Skip to content

MBX Biosciences, Inc. MBX Short- and long-term operating lease liabilities

Short- and long-term operating lease liabilities at other companies

Roivant Sciences logo
Roivant SciencesROIV

Other financials

Income statement

See full
Operating income-$27.3M-2.8%
Net income-$23.5M+1.5%
EPS (diluted)-$0.50+29.6%

Balance sheet

See full
Cash & equivalents$45.2M+51.2%
Total debt$555.0K+327%
Total equity$437.8M+85.9%
Total assets$452.7M+84.1%

Cash flow

See full
Operating cash flow-$20.2M+10.9%
CapEx$437.0K+1,357%
Free cash flow-$20.6M+9.1%

Valuation

See full
Market cap$2.3B+475%
Enterprise value$2.26B+533%

Returns & leverage

See full
Return on equity-25.7%
Debt / equity0.0×
Current ratio30.8×+7.5×

Where this comes from

Reported directly by MBX Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about MBX Biosciences, Inc.'s short- and long-term operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MBX Biosciences, Inc.'s short- and long-term operating lease liabilities?
MBX Biosciences, Inc. (MBX) reported short- and long-term operating lease liabilities of -$41K in Q1 2026.
How has MBX Biosciences, Inc.'s short- and long-term operating lease liabilities changed year-over-year?
MBX Biosciences, Inc.'s short- and long-term operating lease liabilities increased by 2.4% year-over-year, from -$42K to -$41K.